This safety update is a summary of the adverse events (AE) reports which are suspected to be associated with H1N1 vaccines, submitted by healthcare professionals in Singapore to the Health Sciences Authority (HSA). The local reporting of AEs by healthcare professionals forms part of the intensified safety monitoring program of HSA to monitor the safety profile of these products. Other safety monitoring activities include working closely with the World Health Organisation (WHO) and other international drug regulatory authorities to share and review international experiences with these products on a weekly basis, reviewing the data from ongoing clinical trials to further determine the safety profile, and regular review of scientific reports by the manufacturers of these products.

The information will be updated on a regular basis.

• Read more

The product labeling for approved H1N1 vaccines will be updated as new data emerges from on-going clinical studies. For the latest approved product labeling, please refer to the links provided below:

i]  Panvax H1N1 Vaccine and Panvax H1N1 Vaccine Junior Product Labeling (8 Dec 2009) 
ii] Pandemrix H1N1 Vaccine Product Labeling (26 Nov 2009)

The Health Sciences Authority (HSA) has approved the following two H1N1 influenza vaccines on 9 and 15 Oct 2009 respectively:

i] Panvax H1N1 Vaccine by CSL Limited, Australia
ii] Pandemrix H1N1 Injection by Glaxo Smithkline Biologicals

• Read more

Due to the urgent need to produce H1N1 vaccines quickly to meet the demands of the pandemic, the Health Sciences Authority (HSA) is employing a 'rolling review' submission of pandemic vaccines. This approach is similar to drug regulatory authorities around the world, who have developed such mechanisms for expediting the review of pandemic vaccines. 

• Read more

• Read more

• Read more

As voluntary vaccination kicks off, understand how HSA keeps a close watch on the safety profile of the H1N1 vaccines.

• Read more